NO995996L - Fremgangsmåte for behandling av fedme - Google Patents

Fremgangsmåte for behandling av fedme

Info

Publication number
NO995996L
NO995996L NO995996A NO995996A NO995996L NO 995996 L NO995996 L NO 995996L NO 995996 A NO995996 A NO 995996A NO 995996 A NO995996 A NO 995996A NO 995996 L NO995996 L NO 995996L
Authority
NO
Norway
Prior art keywords
treating obesity
obesity
treating
Prior art date
Application number
NO995996A
Other languages
English (en)
Other versions
NO995996D0 (no
NO324818B1 (no
Inventor
Bradford J Duft
Orville G Kolterman
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of NO995996D0 publication Critical patent/NO995996D0/no
Publication of NO995996L publication Critical patent/NO995996L/no
Publication of NO324818B1 publication Critical patent/NO324818B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19995996A 1997-06-06 1999-12-06 Anvendelse av amylin eller en amylinagonist NO324818B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/870,762 US7910548B2 (en) 1997-06-06 1997-06-06 Methods for treating obesity
PCT/US1998/011753 WO1998055144A1 (en) 1997-06-06 1998-06-05 Methods for treating obesity

Publications (3)

Publication Number Publication Date
NO995996D0 NO995996D0 (no) 1999-12-06
NO995996L true NO995996L (no) 2000-02-07
NO324818B1 NO324818B1 (no) 2007-12-10

Family

ID=25356022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995996A NO324818B1 (no) 1997-06-06 1999-12-06 Anvendelse av amylin eller en amylinagonist

Country Status (10)

Country Link
US (1) US7910548B2 (no)
AU (1) AU7823098A (no)
BR (1) BR9809951A (no)
CZ (1) CZ294983B6 (no)
HU (1) HUP0004271A3 (no)
NO (1) NO324818B1 (no)
NZ (1) NZ501451A (no)
PL (1) PL193236B1 (no)
RU (2) RU2207871C2 (no)
WO (1) WO1998055144A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1629849E (pt) * 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US20040022807A1 (en) * 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
ES2316161T3 (es) * 1998-01-09 2009-04-01 Amylin Pharmaceuticals, Inc. Formulaciones para peptidos agonistas de amilina con insulina.
DE60324387D1 (de) * 2002-01-08 2008-12-11 Amylin Pharmaceuticals Inc Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US20060094652A1 (en) * 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
ES2325773T5 (es) † 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
WO2009003666A1 (en) * 2007-06-29 2009-01-08 Lonza Ag Process for the production of pramlintide
RU2403038C2 (ru) * 2008-09-18 2010-11-10 Общество с ограниченной ответственностью "Идеи для здоровья. Группа компаний" Способ лечения и/или профилактики избыточной массы тела, и/или ожирения, и/или метаболических нарушений
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
JP2012523434A (ja) * 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
RU2552221C2 (ru) * 2010-07-15 2015-06-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
ES2640285T3 (es) 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
RU2523558C2 (ru) * 2012-08-22 2014-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Россиской Федерации Способ лечения и повышения качества жизни больных с синдромом диспепсии в сочетании с ожирением
EA035791B1 (ru) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
IL297389A (en) * 2020-04-20 2022-12-01 I2O Therapeutics Inc Use of human amylin analog polypeptides to provide superior glycemic control in type 1 diabetes
MX2024005969A (es) 2022-05-30 2024-06-11 Zealand Pharma As Formulaciones liquidas de analogos de amilina.

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443619A (en) * 1978-12-26 1984-04-17 Hoffmann-La Roche Inc. Chlorocitric acids
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5367052A (en) 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5280014A (en) * 1988-01-11 1994-01-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
IT1219667B (it) * 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
CA2020786A1 (en) * 1989-07-10 1991-01-11 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
AU7316591A (en) * 1990-02-28 1991-09-18 Upjohn Company, The Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
WO1991016917A1 (en) * 1990-05-02 1991-11-14 The Upjohn Company Method of treating gastric ulcers and obesity
SE9003713L (sv) * 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande dietfiberkomposition
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
CA2109794A1 (en) 1991-05-24 1992-11-26 Timothy J. Rink Amylin and possibly insulin containing composition for the treatment of anorexia and related states
DE69219136T2 (de) * 1991-08-26 1997-08-28 Pharmacia & Upjohn Co., Kalamazoo, Mich. Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
MD960317A (ro) 1991-11-19 1998-05-31 Anylin Pharmaceuticals, Inc. Noile peptide-agoniste ale amilinei şi utilizarea lor
DE69317877T2 (de) * 1992-01-21 1998-10-29 Abbott Lab 4''-deoxyerythromycinderivate
US5376638A (en) 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
JPH07509008A (ja) * 1993-05-12 1995-10-05 ユニバーシティ・オブ・シンシナティ アミリン・アンタゴニストおよびアゴニスト
BR9407424A (pt) * 1993-09-07 1996-04-09 Amylin Pharmaceuticals Inc Métodos para regular motilidade gastrointestinal
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
EP0756602B1 (en) * 1994-04-14 1999-06-30 Glaxo Wellcome Inc. Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity
TW448046B (en) * 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
US5766851A (en) * 1995-05-19 1998-06-16 The Johns Hopkins University School Of Medicine Susceptibility gene for obesity and type II diabetes mellitus
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US5646040A (en) * 1995-06-30 1997-07-08 Millennium Pharmaceutical, Inc. Mammalian tub gene
RU2060012C1 (ru) * 1995-08-07 1996-05-20 Ирина Львовна Медкова Способ профилактики и лечения заболеваний, связанных с нарушением липидного обмена
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US5690691A (en) * 1996-05-08 1997-11-25 The Center For Innovative Technology Gastro-intestinal pacemaker having phased multi-point stimulation
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
US5965607A (en) * 1996-12-30 1999-10-12 American Home Products Corporation Substituted Benzo[1,4]dioxines as antiobesity agents
PT1629849E (pt) * 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
US5955443A (en) * 1998-03-19 1999-09-21 Isis Pharmaceuticals Inc. Antisense modulation of PECAM-1
US6100047A (en) * 1999-04-07 2000-08-08 Zen Bio, Inc. Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition

Also Published As

Publication number Publication date
CZ294983B6 (cs) 2005-04-13
CZ9904360A3 (cs) 2000-10-11
US20030026812A1 (en) 2003-02-06
WO1998055144A1 (en) 1998-12-10
RU2314121C9 (ru) 2008-08-10
NO995996D0 (no) 1999-12-06
HUP0004271A3 (en) 2001-08-28
US7910548B2 (en) 2011-03-22
PL338082A1 (en) 2000-09-25
NZ501451A (en) 2001-10-26
BR9809951A (pt) 2000-08-01
AU7823098A (en) 1998-12-21
NO324818B1 (no) 2007-12-10
PL193236B1 (pl) 2007-01-31
RU2207871C2 (ru) 2003-07-10
RU2314121C2 (ru) 2008-01-10
HUP0004271A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
NO995996D0 (no) Fremgangsmåte for behandling av fedme
NO974554D0 (no) Fremgangsmåte for behandling av en underjordisk formasjon
EP0973461A4 (en) MIGRAINE TREATMENT
NO991955L (no) FremgangsmÕte for behandling av hydrokarboner
NO20010117L (no) Fremgangsmåte for behandling av sövnlöshet
NO975159D0 (no) Fremgangsmåte for kontroll av biologisk nedbrytning
NO20003065L (no) Kombinasjon for effektiv behandling av impotens
FI963526L (fi) Menetelmä jätemateriaalin termistä käsittelyä varten
NO982911D0 (no) FremgangsmÕte for behandling av depresjon
GB9707693D0 (en) Novel method of treatment
IS5384A (is) Aðferð til meðferðar á hreyfingartregðu sem er tengd sjúkdómi eða framkölluð með lyfjum
DE69717846D1 (de) Behandlungsverfahren von laktamen
FI973173L (fi) Menetelmä kondensaatin käsittelemiseksi
ID18300A (id) Metoda penemperan
NO982582D0 (no) FremgangsmÕte for behandling av smerte
PL341667A1 (en) Method of treating cooped
DE69812599D1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
NO20006383L (no) Fremgangsmåte for behandling
NO980588D0 (no) Fremgangsmåte for behandling av vann
UA25504A (uk) Спосіб лікуваhhя дисбактеріозу hосоглотки
NO995797L (no) Fremgangsmåte for behandling av isolert systolisk hypertensjon
UA25577A (uk) Спосіб обробки голиhи
UA25636A (uk) Спосіб лікуваhhя hеврозів
UA25349A (uk) Спосіб лікуваhhя гострого деструктивhого паhкреатиту
UA25464A (uk) Спосіб лікуваhhя гострого пієлоhефриту

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ASTRAZENECA PHARMACEUTICALS LP, US

MM1K Lapsed by not paying the annual fees